AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Crescent Biopharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0FSK2
12.82▼ 0.32 (-2.44%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
13.14
Day's Range
12.62 – 13.36
52-Week Range
8.72 – 27.41
Volume
390.2K
Avg Volume
447.2K
Share Statistics
Shares Outstanding
Employees
44
Exchange
XNAS
Listed
2025-06-16
Share count as of July 27, 2026

Crescent Biopharma, Inc. Common Stock (CBIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Crescent Biopharma, Inc. Common Stock (CBIO)
What is Crescent Biopharma, Inc. Common Stock's Market Cap?
Crescent Biopharma, Inc. Common Stock's Market Cap is $476.2M, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's Enterprise Value?
Crescent Biopharma, Inc. Common Stock's Enterprise Value is $308.6M, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's Price / Sales?
Crescent Biopharma, Inc. Common Stock's Price / Sales is 40.1×, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's EV / Revenue?
Crescent Biopharma, Inc. Common Stock's EV / Revenue is 26.0×, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's EV / EBITDA?
Crescent Biopharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's Revenue (TTM)?
Crescent Biopharma, Inc. Common Stock's Revenue (TTM) is $11.9M, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's Net Income (TTM)?
Crescent Biopharma, Inc. Common Stock's Net Income (TTM) is -$165.1M, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's EBITDA?
Crescent Biopharma, Inc. Common Stock's EBITDA is -$168.3M, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's Diluted EPS (TTM)?
Crescent Biopharma, Inc. Common Stock's Diluted EPS (TTM) is -4.45, based on as-reported figures from SEC (XBRL) filings.
What is Crescent Biopharma, Inc. Common Stock's EBITDA Margin?
Crescent Biopharma, Inc. Common Stock's EBITDA Margin is -1416.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CBIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
YoY growth-2.1%+2.1%+33.4%+19.9%
Operating expenses:
Cost of revenues
Selling and marketing
Research and development—
General and administrative
Transaction costs——
Total operating expenses
% of revenue149.3%141.5%99.7%77.3%
(Loss) income from operations
% of revenue-49.3%-41.5%0.3%22.7%
Other (loss) income, net:
Interest income———
Other expense, net
Change in fair value of warrant liability
(Loss) Income before income taxes
Benefit (provision) for income taxes
Net (loss) income
Accretion of Cullgen redeemable convertible preferred stock———
Net loss attributable to noncontrolling interest
Net (loss) income attributable to common stockholders
Net (loss) income per share attributable to common stockholders, basic
Net (loss) income per share attributable to common stockholders, diluted